# A Phase I Study of MEDI9447 (Oleclumab) in Japanese Patients

> **NCT03736473** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 6 (actual)

## Conditions studied

- Advanced Solid Malignancies

## Interventions

- **DRUG:** MEDI9447 (oleclumab)

## Key facts

- **NCT ID:** NCT03736473
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-07
- **Primary completion:** 2019-06-19
- **Final completion:** 2019-06-19
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2019-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03736473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03736473, "A Phase I Study of MEDI9447 (Oleclumab) in Japanese Patients". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT03736473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*